Safety, pharmacokinetics and target engagement of a novel brain penetrant RIPK1 inhibitor (SIR9900) in healthy volunteers with therapeutic potential for neurodegenerative diseases
International Neurology & Brain Disorders Conference, 2024
Safety and efficacy of selective RIPK1 inhibitor SIR1-365 in hospitalized patients with severe COVID-19: A multicenter, randomized, double-blind, phase 1b trial
Journal of Intensive Medicine, 2024
